Diosmin After Hemorrhoidectomy
Diosmin should be administered at 1000 mg twice daily (2000 mg/day total) starting immediately after hemorrhoidectomy and continued for 7-14 days to reduce postoperative bleeding, pain, and other symptoms.
Recommended Dosage and Duration
The optimal regimen based on clinical evidence is:
- Acute post-hemorrhoidectomy phase (Days 1-4): 1500 mg twice daily (3000 mg/day total) - 3 tablets of 500 mg twice daily 1
- Maintenance phase (Days 5-7 to 14): 1000 mg twice daily (2000 mg/day total) - 2 tablets of 500 mg twice daily 1, 2
This dosing strategy is supported by FDA labeling data showing that higher doses (up to 3000 mg/day for 4 days, then 2000 mg/day) significantly improve postoperative symptoms including pain, edema, bleeding, discomfort, and pruritus 1. A randomized controlled trial demonstrated that diosmin 500 mg for 1 week post-hemorrhoidectomy significantly reduced secondary bleeding (0.9% vs 6.1% in controls, p=0.03), with all bleeding episodes occurring 6-15 days post-surgery 3.
Clinical Benefits
Pain and symptom relief: Patients receiving diosmin after Milligan-Morgan hemorrhoidectomy showed statistically significant improvement in pain, heaviness, bleeding, and pruritus from baseline through 8 weeks post-operation (p<0.05) 2. The medication also shortened hospitalization stays significantly 2.
Bleeding prevention: The most compelling evidence supports diosmin's role in reducing secondary hemorrhage risk, which typically occurs 6-15 days after surgery when the eschar separates 3. This is the critical window where diosmin provides maximum benefit.
Wound healing: Proctoscopic examination revealed significant improvement in wound appearance (p<0.001) in patients taking diosmin 2.
Safety Profile and Contraindications
Diosmin demonstrates excellent safety even at doses up to 2000 mg/day for extended periods:
- Common adverse events (similar to placebo): Mild gastrointestinal disturbances (dyspepsia in up to 7% of patients, approximately twice placebo frequency) and headaches 1
- No serious adverse events reported in clinical trials using doses up to 5000 mg/day 1
- No contraindications based on reproductive toxicity studies, hematologic parameters, liver function, or renal function 1, 4
Specific contraindications: None absolute. However, exercise caution with:
- Patients on medications metabolized by CYP450 enzymes (CYP2E1, CYP2C9, CYP3A4), as diosmin may affect drug metabolism of chlorzoxazone, diclofenac, metronidazole, and potentially diltiazem 1
- Grapefruit juice consumption may theoretically affect metabolism, though this has not been specifically documented for diosmin 1
Clinical Context
Important caveat: While established hemorrhoid guidelines from the American Gastroenterological Association do not specifically mention diosmin 5, 6, this reflects the 2004 publication date predating much of the diosmin evidence base. The guidelines emphasize that hemorrhoidectomy complications include bleeding (0.03-6%), with secondary bleeding being a recognized concern 6.
Practical implementation: Start diosmin immediately post-operatively rather than waiting for symptoms to develop, as the medication works prophylactically to prevent secondary bleeding during the critical 6-15 day window 3. The medication can be safely combined with standard post-hemorrhoidectomy care including analgesics, laxatives, and topical treatments without drug interactions 1.
Cost-effectiveness: Despite adding medication cost, diosmin reduces hospitalization time and complication rates, making it cost-effective overall 7.